Kinetic Compatibility as a Predictor of PTP1B Inhibitor Combination Outcomes: An Integrated Experimental and Computational Study
ChemMedChem · 2026
DOI: 10.1002/cmdc.70446 ↗At a glance
Journal article in ChemMedChem, 2026. Written by Jonathan Trapala and 7 co-authors. Institution: Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México. Major MEDLINE topics: Protein Tyrosine Phosphatase, Non-Receptor Type 1, Enzyme Inhibitors. Cited 1 times so far (Crossref); 47 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Although chlorogenic acid, suramin, ursolic acid, and the glycyrrhetinic acid derivative FC122 are individually known PTP1B inhibitors, no study has systematically characterized how mechanistic diversity determines the pharmacological outcome of their combinations. Here, we integrate experimental enzyme kinetics, molecular docking, molecular dynamics (MD), and membrane permeability simulations to address this question. Individual inhibitory potencies ranked SUR > FC122 > UA > CGA (IC 50 : 1.82, 3.27, 6.12, and 252 µM, respectively). Fixed‐ratio combination experiments showed two distinct profiles: additivity for the uncompetitive + mixed pair (FC122 + UA) and competitive + competitive pairs (SUR + CGA), and antagonism for the competitive + uncompetitive combination (SUR + FC122). Docking and MD provided the structural basis for these results and suggested that each combination imposes a distinct structural flexibility profile on the disordered C‐terminal region of PTP1B (residues 300–400). For the first time, the MD‐AMBER‐Umbrella‐COM protocol was applied to generate a comparative membrane permeability profile for mechanistically diverse PTP1B inhibitors, proposing a permeability order (SUR > FC122 > CGA ≈ UA). These results suggest that kinetic compatibility is a more reliable predictor of promising inhibitor combinations than binding‐site geography alone, and they offer a rational framework for designing multisite PTP1B inhibition strategies in type 2 diabetes mellitus.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, México.
- Laboratorio de Síntesis y Aislamiento de Sustancias Bioactivas, Departamento de Sistemas Biológicos, División de Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana - Unidad Xochimilco, Ciudad de Méxic…
ORCID profiles: Laura I Álvarez-Añorve, Nathaly Vasquez-Martínez, Erika Chavira-Suárez, Luz Vásquez-Bochm, Francisco Cortés-Benítez, Martin González-Andrade
Cite
APA
Trapala, J., Álvarez-Añorve, L. I., Vasquez-Martínez, N., Chavira-Suárez, E., Vásquez-Bochm, L., Matuz-Mares, D., Cortés-Benítez, F., & González-Andrade, M. (2026). Kinetic Compatibility as a Predictor of PTP1B Inhibitor Combination Outcomes: An Integrated Experimental and Computational Study. ChemMedChem. https://doi.org/10.1002/cmdc.70446
Vancouver
Trapala J, Álvarez-Añorve LI, Vasquez-Martínez N, Chavira-Suárez E, Vásquez-Bochm L, Matuz-Mares D, et al. Kinetic Compatibility as a Predictor of PTP1B Inhibitor Combination Outcomes: An Integrated Experimental and Computational Study. ChemMedChem. 2026. doi:10.1002/cmdc.70446
BibTeX
@article{Trapala2026,
author = {Trapala, Jonathan and Álvarez-Añorve, Laura I and Vasquez-Martínez, Nathaly and Chavira-Suárez, Erika and Vásquez-Bochm, Luz and Matuz-Mares, Deyamira and Cortés-Benítez, Francisco and González-Andrade, Martin},
title = {Kinetic Compatibility as a Predictor of PTP1B Inhibitor Combination Outcomes: An Integrated Experimental and Computational Study},
journal = {ChemMedChem},
year = {2026},
doi = {10.1002/cmdc.70446}
}
EUVIMED